Scarica l'app Stockscreener
47.42
0.13%
0.06
Dopo l'orario di chiusura:
47.42
Rapport Therapeutics Inc Borsa (RAPP) Ultime notizie
Johnson & Johnson Purchases New Stake in Rapport Therapeutics, Inc. $RAPP - MarketBeat
How Rapport Therapeutics Inc. (RAPP) Affects Rotational Strategy Timing - Stock Traders Daily
Walleye Capital LLC Purchases Shares of 102,163 Rapport Therapeutics, Inc. $RAPP - MarketBeat
Brokers Offer Predictions for RAPP Q1 Earnings - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) CEO Abraham Ceesay Sells 28,958 Shares - MarketBeat
Abraham Ceesay Sells 22,541 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
Rapport Therapeutics (RAPP) CEO Abraham Ceesay sells 51,499 shares via 10b5-1 plan - Stock Titan
Rapport Therapeutics (NASDAQ:RAPP) Given New $66.00 Price Target at HC Wainwright - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Sets New 1-Year HighTime to Buy? - MarketBeat
Rapport Therapeutics, Inc. $RAPP Shares Bought by Dimensional Fund Advisors LP - MarketBeat
Do Widening Losses At Rapport Therapeutics (RAPP) Reveal Strategic Investment Or Emerging Financial Strain? - webull.com
Q3 Earnings Estimate for RAPP Issued By HC Wainwright - MarketBeat
Rapport Therapeutics Inc (RAPP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rapport Therapeutics (NASDAQ:RAPP) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Rapport Therapeutics Inc (RAPP) Stock News Today - TradingKey
Analysts Offer Insights on NA Companies: Starz Entertainment Corp (STRZ), Bluelinx Holdings (BXC) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Analysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (RAPP) and Honeywell Aerospace (HONA) - The Globe and Mail
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Rapport Therapeutics stock hits all-time high at 44.38 USD By Investing.com - Investing.com India
Rapport Therapeutics stock hits all-time high at 44.38 USD - Investing.com
Rapport Therapeutics (NASDAQ:RAPP) Reaches New 52-Week HighHere's What Happened - MarketBeat
Rapport Therapeutics: Advancing Phase 3 Epilepsy Pipeline and De-Risked Development Path Underpins Buy Rating - TipRanks
Rapport Therapeutics (NASDAQ:RAPP) Announces Earnings Results - MarketBeat
Rapport Therapeutics' (RAPP) "Buy" Rating Reiterated at BTIG Research - MarketBeat
Rapport Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Rapport Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
(RAPP) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Rapport Therapeutics, Inc. Q2 2026: Revenue $0 EPS $(1.19) — 10-Q Summary - TradingView
Rapport Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
Rapport Therapeutics (Nasdaq: RAPP) books $20,000 from RAP-219 China deal - Stock Titan
Rapport Therapeutics reports Q2 2026 net loss $56.6M, cash $436.1M, advances RAP-219 to Phase 3 - TradingView
Rapport Therapeutics Reports $56.6 Million Q2 Net Loss - Quiver Quantitative
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update - The Manila Times
RAPP Q2'26 Earnings: EPS estimate is (0.96) USD - TradingView
Rapport Therapeutics, Inc. (RAPP) Stock Report: Analyst Consensus Suggests a 36.95% Upside Potential - DirectorsTalk Interviews
RAPP Q2'26 Earnings: revenue estimate is 0 USD - TradingView
William Blair Initiates Rapport Therapeutics at Outperform - marketscreener.com
Rapport Therapeutics Inc (RAPP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
William Blair initiates Rapport Therapeutics stock with outperform rating By Investing.com - Investing.com India
Rapport Therapeutics, Inc. Revenue Breakdown – NASDAQ:RAPP - TradingView
Rapport Therapeutics Inc (RAPP) Valuation: PE, PB & Fair Value Analysis - TradingKey
William Blair initiates Rapport Therapeutics stock with outperform rating - Investing.com
William Blair Initiates Rapport Therapeutics(RAPP.US) With Buy Rating - Moomoo
Rapport Therapeutics Inc (RAPP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rapport Therapeutics Inc (RAPP) Income Statement - TradingKey
Rapport Therapeutics Market Sentiment - Benzinga España
RAPP|Rapport Therapeutics Inc|Price:41.660|Chg%:+0.870 - TradingKey
Rapport Therapeutics Inc (RAPP) Institutional Confidence - TradingKey
Rapport Therapeutics Inc (RAPP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
RAPP|Rapport Therapeutics Inc|Price:40.680|Chg%:-0.700 - TradingKey
RAPP|Rapport Therapeutics Inc|Price:40.980|Chg%:-1.800 - TradingKey
Rapport Therapeutics Inc (RAPP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RAPP|Rapport Therapeutics Inc|Price:41.992|Chg%:+1.202 - TradingKey
Rapport Therapeutics Inc (RAPP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Rapport Therapeutics Inc (RAPP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Price to earnings forward of Rapport Therapeutics, Inc. – NASDAQ:RAPP - TradingView
Price to sales forward of Rapport Therapeutics, Inc. – NASDAQ:RAPP - TradingView
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Exploring a 37% Potential Upside in CNS Therapeutics - DirectorsTalk Interviews
Responsive Playbooks and the RAPP Inflection - Stock Traders Daily
Siren L.L.C. Lowers Stock Holdings in Rapport Therapeutics, Inc. $RAPP - MarketBeat
Goldman Sachs Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Raises Target Price to $58 - Moomoo
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):